ArticleMMWR. Morbidity and mortality weekly report2024
Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 - Veterans Health Administration, March-September 2022.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Prevalence and healthcare burden of inappropriate antimicrobial treatment in patients at high risk of complications from acute respiratory infections: a scoping review.Frontiers in medicine · 2025Pooled it
- A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose-Ranging Study.Clinical and translational science · 2026Trial
- Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Primary care physicians' perspectives on managing mild-to-moderate COVID-19 in populations at risk for progression to severe disease: a survey-based study.BMC primary care · 2026Article
- Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study.BMC infectious diseases · 2026Article
- Real-world impact of point-of-care testing for SARS-CoV-2 in an ambulatory setting of an integrated health network.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Impact of in-hospital SARS-CoV-2 infection on mortality and outcomes in patients admitted for heart failure: a nationwide analysis in Brazil.Frontiers in cardiovascular medicine · 2026Article
- Impact of Risk Stacking on COVID-19-Related Healthcare Utilization: A Real-World Retrospective Cohort Study.Infectious diseases and therapy · 2026Article
- Pharmacist follow-up of patients prescribed nirmatrelvir/ritonavir: a single-center retrospective analysis.Journal of pharmaceutical health care and sciences · 2025Article
- Primary Findings of Nationwide Home-based Test to Treat Program for COVID-19 and Influenza.medRxiv : the preprint server for health sciences · 2025Article
- Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study.Open forum infectious diseases · 2025Article
- Leveraging near-real-time patient and population data to incorporate fluctuating risk of severe COVID-19: development and prospective validation of a personalised risk prediction tool.EClinicalMedicine · 2025Article
- Pulmonary aspergillosis in US Veterans with COVID-19: a nationwide, retrospective cohort study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Factors associated with seeking and receiving home antiviral therapy during the coronavirus disease 2019 (COVID-19) pandemic.Discover public health · 2025Article
- Perceptions and Barriers to Outpatient Antiviral Therapy for COVID-19 and Influenza as Observed by Infectious Disease Specialists in North America: Results of an Emerging Infections Network (EIN) Survey, February 2024.Open forum infectious diseases · 2024Article
- Low antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with COVID-19 in Taiwan in 2022.Journal of global health · 2024Article
- Perceived Risk for Severe COVID-19 and Oral Antiviral Use Among Antiviral-Eligible US Adults.Infectious diseases and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiviral drugs reduce the rate of progression to severe COVID-19 when given to patients with mild-to-moderate disease within 5 days of symptom onset. Despite being recommended for patients at high risk for progression to severe COVID-19 because of age or chronic conditions, reported antiviral use among the general adult population has been ≤35%. To ascertain reasons for underuse of antiviral medications to prevent severe COVID-19 and propose interventions accordingly, a detailed review was conducted of 110 Veterans Health Administration patients with mild-to-moderate infection at high risk for progression because of underlying conditions (organ transplantation or hematologic malignancies) who did not receive an antiviral drug. Among these 110 patients, all of whom had received COVID-19 vaccine, 22 (20.0%) were offered treatment but declined, and 88 (80.0%) were not offered treatment. Among the 88 patients not offered treatment, provider reasons included symptom duration of >5 days (22.7%), concern about possible drug interactions (5.7%), or absence of symptoms (22.7%); however, among nearly one half (43 of 88; 48.9%) of these patients, no reason other than mild symptoms was given. Among 24 (55.8%) of those 43 patients, follow-up was limited to telephone calls to report test results and inquire about symptom evolution, with no documentation of treatment being offered. These findings suggest that education of patients, providers, and medical personnel tasked with follow-up calls, combined with advance planning in the event of a positive test result, might improve the rate of recommended antiviral medication use to prevent severe COVID-19-associated illness, including death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.